Allogene Therapeutics (ALLO) Intangibles (2018 - 2019)
Allogene Therapeutics (ALLO) posted Intangibles of $151000.0 for Q4 2019, down 49.83% sequentially from $301000.0 in Q3 2019, and down 79.97% YoY from $754000.0 in Q4 2018.
Allogene Therapeutics (ALLO) Intangibles (2018 - 2019) Analysis & Trends
Allogene Therapeutics has reported Intangibles for 2 years, with the latest figure at $151000.0 in Q4 2019.
- Quarterly Intangibles fell 79.97% year-over-year to $151000.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $151000.0 (down 79.97% YoY) and the FY2019 annual result came in at $151000.0, down 79.97% from the prior year.
- Intangibles slipped to $151000.0 in Q4 2019 per ALLO's latest filing, from $301000.0 in the prior quarter.
- Over five years, Intangibles peaked at $904000.0 in Q3 2018 and troughed at $151000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 151,000.00 |
| Sep 30, 2019 | 301,000.00 |
| Jun 30, 2019 | 452,000.00 |
| Mar 31, 2019 | 603,000.00 |
| Dec 31, 2018 | 754,000.00 |
| Sep 30, 2018 | 904,000.00 |